Stocky turns companies like AXGN into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. Axogen trades at a 70× forward P/E on modest 28/100 compounder fundamentals, with a 54/100 Leadership Alignment score reflecting weak governance depth. The core risk is FDA regulatory discretion on the Avance Nerve Graft—enforcement ended December 2025 with BLA approval, shifting reimbursement and market access uncertainty. Expired royalty obligations offer some relief, but cannot offset valuation risk and execution headwinds.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for AXGN:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 24/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates AXGN (AXGN) at 24/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. Axogen trades at a 70× forward P/E on modest 28/100 compounder fundamentals, with a 54/100 Leadership Alignment score reflecting weak governance depth. The core risk is FDA regulatory discretion on the Avance Nerve Graft—enforcement
AXGN's current Stocky Verdict is 24/100, placing it in the "Avoid" band. This composite combines a 28/100 Compounder score, 54/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for AXGN yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
AXGN scores 54/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
AXGN's Vulnerability Profile scores 25/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to AXGN.
Sign up free and unlock the full analysis on AXGN — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for AXGN in the app.
